Brown Foundation Institute of Molecular Medicine McGovern Medical School at The University of Texas Health Science Center (UTHealth) Houston TX USA.
Department of Biosciences Rice University Houston TX USA.
J Am Heart Assoc. 2023 Aug 15;12(16):e028880. doi: 10.1161/JAHA.122.028880. Epub 2023 Aug 7.
Background Peripheral arterial disease and critical limb ischemia are cardiovascular complications associated with vascular insufficiency, oxidative metabolic dysfunction, and myopathy in the limbs. Estrogen-related receptor gamma (ERRγ) has emerged as a dual regulator of paracrine angiogenesis and oxidative metabolism through transgenic mouse studies. Here our objective was to investigate whether postischemic intramuscular targeting of ERRγ via gene therapy promotes ischemic recovery in a preclinical model of peripheral arterial disease/critical limb ischemia. Methods and Results Adeno-associated virus 9 (AAV9) gene delivery vector was developed and first tested via intramuscular injection in murine skeletal muscle. AAV9-Esrrg robustly increased ERRγ protein expression, induced angiogenic and oxidative genes, and boosted capillary density and succinate dehydrogenase oxidative metabolic activity in skeletal muscles of C57Bl/6J mice. Next, hindlimb ischemia was induced via unilateral femoral vessel ligation in mice, followed by intramuscular AAV9-Esrrg (or AAV9-green fluorescent protein) gene delivery 24 hours after injury. ERRγ overexpression increased ischemic neoangiogenesis and markers of endothelial activation, and significantly improved ischemic revascularization measured using laser Doppler flowmetry. Moreover, ERRγ overexpression restored succinate dehydrogenase oxidative metabolic capacity in ischemic muscle, which correlated with increased mitochondrial respiratory complex protein expression. Most importantly, myofiber size to number quantification revealed that AAV9-Esrrg restores myofibrillar size and mitigates ischemia-induced myopathy. Conclusions These results demonstrate that intramuscular AAV9-Esrrg delivery rescues ischemic pathology after hindlimb ischemia, underscoring that gene therapy or pharmacological activation could be a promising strategy for the management of peripheral arterial disease/critical limb ischemia.
外周动脉疾病和肢体严重缺血是与血管功能不全、氧化代谢功能障碍和肢体肌病相关的心血管并发症。雌激素相关受体γ(ERRγ)通过转基因小鼠研究,已成为旁分泌血管生成和氧化代谢的双重调节剂。本研究旨在探讨通过基因治疗在肢体外周动脉疾病/严重肢体缺血的临床前模型中,是否可以实现缺血后肌肉内靶向 ERRγ 以促进缺血恢复。
开发了腺相关病毒 9(AAV9)基因传递载体,并首先通过肌肉内注射在小鼠骨骼肌中进行了测试。AAV9-Esrrg 可显著增加 ERRγ 蛋白表达,诱导血管生成和氧化基因,并增加 C57Bl/6J 小鼠骨骼肌中的毛细血管密度和琥珀酸脱氢酶氧化代谢活性。接下来,通过单侧股血管结扎在小鼠中诱导后肢缺血,在损伤后 24 小时通过肌肉内 AAV9-Esrrg(或 AAV9-绿色荧光蛋白)基因传递。ERRγ 过表达增加了缺血性新生血管形成和内皮激活标志物,并通过激光多普勒血流仪显著改善了缺血性再血管化。此外,ERRγ 过表达恢复了缺血肌肉中的琥珀酸脱氢酶氧化代谢能力,这与增加的线粒体呼吸复合物蛋白表达相关。最重要的是,肌纤维大小与数量的定量分析表明,AAV9-Esrrg 恢复了肌纤维大小,并减轻了缺血引起的肌病。
这些结果表明,后肢缺血后,肌肉内 AAV9-Esrrg 传递可挽救缺血性病变,强调基因治疗或药物激活可能是治疗外周动脉疾病/肢体严重缺血的有前途的策略。